Aardvark Therapeutics
AARD
35 hedge funds and large institutions have $121M invested in Aardvark Therapeutics in 2025 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 13 increasing their positions, 3 reducing their positions, and 9 closing their positions.
333% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 3
89% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 9
85% more capital invested
Capital invested by funds: $65.1M → $121M (+$55.4M)
30% more funds holding
Funds holding: 27 → 35 (+8)
0.47% more ownership
Funds ownership: 40.63% → 41.09% (+0.47%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.04M |
| 2 |
BlackRock
New York
|
+$1.93M |
| 3 |
LCM
Laurion Capital Management
New York
|
+$1.86M |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$1.72M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
+$1.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
-$3.75M |
| 2 |
SCM
Suvretta Capital Management
New York
|
-$2.35M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$773K |
| 4 |
Millennium Management
New York
|
-$493K |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$266K |
AARD Hedge Fund Activity: Q2 2025 in Review
35 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Aardvark Therapeutics (AARD) for Q2 2025, worth a combined $121M — up 85% from $65.1M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new AARD positions and 9 closed out — a net gain of 8 holders — while 13 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, adding an estimated $3.04M. The largest seller was Braidwell, exiting entirely with an estimated $3.75M sold.
- 35 institutional investors held Aardvark Therapeutics (AARD) as of Q2 2025, up from 27 in Q1 2025.
- Funds reported $121M of Aardvark Therapeutics stock for Q2 2025, up 85% quarter-over-quarter.
- 17 funds opened new Aardvark Therapeutics positions in Q2 2025 and 9 closed out, a net change of +8 holders.
- The largest Aardvark Therapeutics buyer in Q2 2025 was Vanguard Group, an estimated $3.04M added.
- The largest Aardvark Therapeutics seller in Q2 2025 was Braidwell, an estimated $3.75M sold.
Based on aggregated 13F filings for Q2 2025.